Recombinant Human Arylsulfatase A/ARSA Protein，His

Arylsulfatase A (ARSA) is a crucial enzyme involved in the catabolism of sulfated glycosaminoglycans and is primarily expressed in the lysosomes. Deficiency of ARSA leads to a rare genetic disorder known as Metachromatic Leukodystrophy (MLD), characterized by the accumulation of sulfated lipids, demyelination, and neurodegeneration. Given the severe neurological implications of ARSA deficiency, there has been a significant focus on developing therapeutic strategies, including enzyme replacement therapy (ERT). The recombinant production of ARSA has become a central aspect of these efforts. Understanding the structure-function relationships of ARSA, optimizing its production in various expression systems, and enhancing its stability and delivery are vital for developing effective treatment options for MLD patients. Recent advancements in recombinant DNA technology have enabled the generation of functional and commercially viable ARSA proteins, paving the way for clinical applications. Furthermore, the exploration of potential gene therapy approaches and small molecule pharmacological chaperones is also underway to correct the underlying genetic defects associated with ARSA deficiency. As research continues to unfold, the dual focus on the biochemical characterization of ARSA and the evaluation of innovative therapeutic modalities represents a promising frontier in the battle against MLD and related lysosomal storage disorders.